CLINICAL TRIAL

LYNX - NCT01265719

Pediatric RED

Observational

Phase 4

Long-Term Non-Interventional Latanoprost Study

Rare Eye Disease concerned by the trial :
congenital Glaucoma

Status of the trial : completed

Orphan drug recognition : No

Inclusion criteria : Diagnosis of pediatric glaucoma or elevated intraocular pressure, continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination

Exclusion criteria : Pregnant or nursing females at baseline, a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost

Inclusion opening date : 23/12/2010

Inclusion closing date : 12/10/2017

Children ☑

Adults ☐

Within ERN-EYE members

Locations of the trial :

Universitätsklinikum Gießen und Marburg GmbH
Friedrichstr. 18, 35392 Gießen, Germany

Rigshospitalet - Glostrup
Valdemar Hansens Vej 1, Glostrup, Danemark

Bambino Gesù Children's Hospital of Rome
Piazza di Sant'Onofrio, 00165 Roma RM, Italy

Central Manchester University Hospitals NHS Foundation Trust, MAHSC
Cobbett House, Manchester Royal Infirmary
Oxford Rd, Manchester, UK

Fondation Ophtalmologique Adolphe de Rothschild
29 rue Manin , 75019 Paris, France

HU Necker - Enfants Malades, AP-HP
149 rue de Sèvres, 75015 Paris, France



Funder type : Drug company - Industry

More informations